Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50
Received 22 March 2018
Accepted for publication 11 July 2018
Published 4 October 2018 Volume 2018:10 Pages 145—150
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jan Colli
Ilan Gielchinsky,1,2 Matthijs J Scheltema,1 Thomas Cusick,1 John Chang,1,2 Ron Shnier,3,4 Daniel Moses,4,5 Warick Delprado,4,6 Quoc Nguyen,1 Carlo Yuen,4,7 Anne-Maree Haynes,1 Phillip D Stricker1,2,4,7
1Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; 2St Vincent’s Prostate Cancer Centre, Darlinghurst, NSW, Australia; 3Southern Radiology, Randwick, NSW, Australia; 4School of Medicine, University of New South Wales, Kensington, NSW, Australia; 5Spectrum Radiology, Randwick, NSW, Australia; 6Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia; 7St Vincent’s Clinic, Sydney, NSW, Australia
Introduction: Three percent of all new diagnosed prostate cancer (PC) patients are under the age of 50. Multiparametric MRI (mpMRI) is considered as increasingly powerful tool for decision-making in diagnosis of PC and in some active surveillance protocols. Since prostate architecture changes with age, we evaluated the sensitivity of mpMRI to detect clinically significant PC in patients under the age of 50 compared to pair-matched older patients.
Methods: Data from a prospective collected and ethics approved database were retrospectively analyzed. We reviewed 1,395 records of PC patients from the years 2012–2017, identifying those under the age of 50 who had radical prostatectomy as primary treatment, a pre-operative mpMRI, a full clinical data set and who had clinically significant cancer (N=51). Tumor size and International Society of Urological Pathology (ISUP) score pair-matching was performed for patients older than 55 years. Clinically significant cancer was defined as ISUP >2 or ISUP 2 with >5% Gleason 4. The sensitivity to detect clinically significant cancer with mpMRI was calculated using pre-operative Prostate Imaging Reporting and Data System (PI-RADS) score and whole-gland final pathology.
Results: The median patient age in the young and older groups was 47 and 62, respectively. Both cohorts matched significantly regarding tumor volume (P =0.91) and ISUP score (P =1.0). The median PI-RADS score for the young group was 3, and 4 for the older group. The sensitivity for mpMRI, for PI-RADS 3,4 and 5 was 80.3% (95% CI 66.8%–90.1%) in the young group and 84.3% in the older group (95% CI 71.4%–92.9%), demonstrating no statistically significant difference (P=0.603). Sensitivity of mpMRI for PI-RADS 4,5 was 49.0% (95% CI 34.7%–63.4%) for the young group and 72.5% (95% CI 58.2%–84.1%) for the older group, which differ significantly (P=0.014).
Conclusions: mpMRI may have a reduced sensitivity for detecting clinically significant PC in patients under the age of 50 for PI-RADS score 4,5 lesions. Many significant PC lesions were reported as PI-RADS 3 under the age of 50. We recommend that increased significance is placed on PI-RADS 3 lesions found in patients under the age of 50.
Keywords: mpMRI, prostate cancer, young, sensitivity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]